Table 4.
Cox proportional hazard analyses of New York Langone external validation cohort.
| Covariate | Univariate analysis NYU (HR) |
Multivariate analysis NYU (HR) |
|---|---|---|
| Biomarker | 4.79 (CI 2.09–10.96; p = 0.0002) | 3.02 (CI 1.10–8.29; p = 0.03) |
| preop. PSA (ng/mL) | 1.07 (CI 1.02–1.12; p = 0.004) | |
| ISUP grade | ||
| 1 | 1.0 | |
| 2 | 2.64 (CI 0.73–9.58; p = 0.14) | |
| 3 | 8.74 (CI 2.16–35.30; p = 0.00) | |
| 4 | 12.78 (CI 2.82–57.91; p = 0.00) | |
| 5 | 9.60 (CI 2.32–39.69; p = 0.00) | |
| Pathological stage | ||
| pT2a + b | 1.0 | |
| pT2c | 1.02 (CI 0.27–3.80; p = 0.98) | |
| pT3a | 1.26 (CI 0.28–5.67; p = 0.77) | |
| pT3b | 2.77 (CI 0.66–11.62; p = 0.16) | |
| Surgical margins | ||
| Free | 1.0 | |
| Focal | 2.13 (CI 0.76–5.96; p = 0.15) | |
| Widespread | 0.20 (CI 0.01–3.39; p = 0.27) |